Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Das28

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    377 result(s) found for: Das28. Displaying page 1 of 19.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-002067-20 Sponsor Protocol Number: RA0077 Start Date*: 2012-06-13
    Sponsor Name:UCB Pharma SA
    Full Title: A multicenter, single blind, randomized parallel group study to assess the short and long term efficacy of certolizumab pegol plus methotrexate compared with adalimumab plus methotrexate in subject...
    Medical condition: Moderate to severe rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) PT (Completed) AT (Completed) IE (Completed) CZ (Completed) ES (Completed) BG (Completed) FR (Completed) IT (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001729-25 Sponsor Protocol Number: RA0055 Start Date*: 2012-03-05
    Sponsor Name:UCB Pharma SA
    Full Title: A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol in combination with methotrexate for inducing and sustaining clinical re...
    Medical condition: Early active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IE (Completed) HU (Completed) ES (Completed) CZ (Completed) AT (Completed) SE (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002156-27 Sponsor Protocol Number: 1356/2015 Start Date*: Information not available in EudraCT
    Sponsor Name:Medical University of Vienna
    Full Title: Prospective controlled study of reduced-dose Rituximab in rheumatoid arthritis patients in low disease activity and remission – the REDOREM study
    Medical condition: rheumatoid arthritis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001114-26 Sponsor Protocol Number: M14-500 Start Date*: 2014-11-10
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) GB (Completed) SE (Completed) ES (Completed) HU (Completed) IT (Completed) NL (Completed) AT (Completed) GR (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004051-20 Sponsor Protocol Number: FER-TOC-2013-01 Start Date*: 2014-02-26
    Sponsor Name:FUNDACIÓN ESPAÑOLA DE REUMATOLOGIA
    Full Title: NOT CONTROLLED STUDY TO ASSESS THE EFFICACY OF TOCILIZUMAB IN PATIENTS WITH MODERATE OR SEVERE RHEUMATOID ARTHRITIS WHO ARE CANDIDATES TO BE TREATED WITH A BIOLOGICAL THERAPY AS MONOTHERAPY
    Medical condition: RHEUMATOID ARTHRITIS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-005102-68 Sponsor Protocol Number: IM101-064 Start Date*: 2005-09-01
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects with Active Rheumatoid Arthritis on Background Non-Biologic DMARD...
    Medical condition: RHEUMATOID ARTHRITIS,NOS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) ES (Completed) DE (Completed) BE (Completed) IT (Completed) CZ (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2015-002809-12 Sponsor Protocol Number: YLB113-002 Start Date*: 2015-11-17
    Sponsor Name:YL Biologics Ltd
    Full Title: A comparative Study to Assess the Efficacy, Safety and Immunogenicity of YLB113 and Enbrel for the Treatment of Rheumatoid Arthritis
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) CZ (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-020738-24 Sponsor Protocol Number: Version 1.2 (20/06/2011) Start Date*: 2010-10-12
    Sponsor Name:King's College London
    Full Title: Optimising Treatment With Tumour Necrosis Factor Inhibitors In Rheumatoid Arthritis: Is Dose Tapering Practical In Good Responders? A “Proof Of Principle” And Exploratory Trial. (OPTTIRA)
    Medical condition: Patients with established Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000337-13 Sponsor Protocol Number: PreCePra Start Date*: 2013-05-13
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in RA (P...
    Medical condition: Patients with active Rheumatoid Artrhitis (DAS28 > 3.2) despite DMARD therapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023692-26 Sponsor Protocol Number: D4300C00004 Start Date*: 2011-04-07
    Sponsor Name:AstraZeneca AB
    Full Title: (OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared with Adalimumab M...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-019694-15 Sponsor Protocol Number: ML25252 Start Date*: 2010-09-28
    Sponsor Name:N.V. Roche S.A.
    Full Title: Act-Alone : An open-label, single-arm study to describe glucocorticoid use in rheumatoid arthritis patients treated with Tocilizumab in daily clinical practice and to evaluate systematic glucocorti...
    Medical condition: Rheumatoid Arthritis in adult
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005309-35 Sponsor Protocol Number: CL04041024 Start Date*: 2017-06-16
    Sponsor Name:R-Pharm
    Full Title: A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis
    Medical condition: Moderately to Severely Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) LT (Completed) CZ (Completed) HU (Completed) PL (Completed) BG (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2014-003453-34 Sponsor Protocol Number: 201755 Start Date*: 2015-06-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheuma...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) HU (Completed) CZ (Completed) ES (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001027-20 Sponsor Protocol Number: CACZ885GDE01T Start Date*: 2012-04-03
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension.
    Medical condition: adult onset Still's disease (AOSD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042061 Still's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005777-20 Sponsor Protocol Number: TMP-1115_01 Start Date*: 2016-12-12
    Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Translational Medicine and Pharmacology ITMP
    Full Title: Impact of concomitant Methotrexate on efficacy, safety and adherence of Ustekinumab-treatment in patients with active Psoriatic Arthritis (MUST-Study)
    Medical condition: active psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004539-54 Sponsor Protocol Number: TMP-0731-2018 Start Date*: 2019-06-03
    Sponsor Name:Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP
    Full Title: Capability of Tofacitinib or Etanercept to accelerate clinical relevant tapering of non-steroidal anti-inflammatory drugs and treat-to-target guided de-escalation of corticosteroids in patients wit...
    Medical condition: Patients with active Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006040-79 Sponsor Protocol Number: ML28169 Start Date*: 2012-05-25
    Sponsor Name:Aarhus University Hospital, Department of Rheumatology U
    Full Title: The efficacy and safety of adding tocilizumab to methotrexate and intra-articular glucocorticosteroid treatment in early rheumatoid arthritis. A randomized, double-blinded, placebo-controlled tria...
    Medical condition: Adult Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012218-30 Sponsor Protocol Number: ML22648 Start Date*: 2009-10-06
    Sponsor Name:Roche Farmacêutica Química, Lda.
    Full Title: A randomized, double-blind, placebo-controlled study to assess the efficacy of tocilizumab (TCZ) + non-biological DMARD in reducing synovitis as measured by magnetic resonance imaging (MRI) at 12 w...
    Medical condition: Men and women > 18 years of age with RA who are currently experiencing an inadequate clinical response to a stable dose of non-biologic DMARDs (at least 12 weeks) and with MRI documented synovitis ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004673-16 Sponsor Protocol Number: MA29585 Start Date*: 2016-01-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Prospective, multicentre, placebo-controlled, double-blind study to compare the efficacy of maintenance treatment with tocilizumab with or without glucocorticoid discontinuation in rheumatoid arth...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004834-11 Sponsor Protocol Number: CR6086-2-02 Start Date*: 2017-07-06
    Sponsor Name:Rottapharm Biotech S.r.l.
    Full Title: A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 o...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BG (Completed) PL (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:01:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA